Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Eisen

Showing results (61-70 of 116) with videos related to

Pageof 12
Sort By:
Human Genetics|October 28, 2003
Inherited variants in MYH are unlikely to contribute to the risk of lung carcinomaNada Al-Tassan, Tim Eisen, Julie Maynard, et al.
European Urology Open Science|August 4, 2025
Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE TrialsBhavna Oza, Eleni Frangou, Tim Eisen, et al.
Investigational New Drugs|April 30, 2013
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II studyTim Eisen, Yaroslav Shparyk, Nicholas Macleod, et al.
Magnetic Resonance Imaging|December 3, 2014
The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI dataAndrew B Gill, Gayathri Anandappa, Andrew J Patterson, et al.
World Journal of Urology|December 20, 2017
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weightingTobias Klatte, Kate Fife, Sarah J Welsh, et al.
Investigational New Drugs|August 5, 2010
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanomaSimon Pacey, Martin Gore, David Chao, et al.
Cancer Research Communications|April 16, 2026
Multiplexed P21/MCM-2 detection predicts relapse and may identify tyrosine kinase inhibitor-resistant patients in clear cell renal cell carcinomaHazem Abdullah, In Hwa Um, Grant D Stewart, et al.
European Urology|June 28, 2011
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic diseaseJean-Jacques Patard, Geraldine Pignot, Bernard Escudier, et al.
Thorax|July 5, 2011
CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST reportJohn Kirkpatrick Field, David Baldwin, Kate Brain, et al.
Thorax|January 30, 2013
Authors' responseJohn K Field, David Baldwin, Kate Brain, et al.
Pageof 12

Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
Human Genetics|October 28, 2003
Inherited variants in MYH are unlikely to contribute to the risk of lung carcinomaNada Al-Tassan, Tim Eisen, Julie Maynard, et al.
European Urology Open Science|August 4, 2025
Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE TrialsBhavna Oza, Eleni Frangou, Tim Eisen, et al.
Investigational New Drugs|April 30, 2013
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II studyTim Eisen, Yaroslav Shparyk, Nicholas Macleod, et al.
Magnetic Resonance Imaging|December 3, 2014
The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI dataAndrew B Gill, Gayathri Anandappa, Andrew J Patterson, et al.
World Journal of Urology|December 20, 2017
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weightingTobias Klatte, Kate Fife, Sarah J Welsh, et al.
Investigational New Drugs|August 5, 2010
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanomaSimon Pacey, Martin Gore, David Chao, et al.
Cancer Research Communications|April 16, 2026
Multiplexed P21/MCM-2 detection predicts relapse and may identify tyrosine kinase inhibitor-resistant patients in clear cell renal cell carcinomaHazem Abdullah, In Hwa Um, Grant D Stewart, et al.
European Urology|June 28, 2011
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic diseaseJean-Jacques Patard, Geraldine Pignot, Bernard Escudier, et al.
Thorax|July 5, 2011
CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST reportJohn Kirkpatrick Field, David Baldwin, Kate Brain, et al.
Thorax|January 30, 2013
Authors' responseJohn K Field, David Baldwin, Kate Brain, et al.
Pageof 12